A medical technology company focused on developing and commercializing minimally invasive solutions for patients with obstructive sleep apnea. Inspire's FDA-approved neurostimulation device offers an alternative to CPAP machines, positioning it in a high-growth niche of the sleep disorder treatment market. Investors monitor its revenue growth as adoption expands among the estimated 30 million Americans with sleep apnea.
1 member of Congress has disclosed 1 trade in Inspire Medical Systems, Inc. (INSP), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-04-10 | Daniel Goldman | sell | $1K – $15K |